To convert your AI ambitions into compounding enterprise value, biopharma leaders must shift from managing a collection of pilots to operating a disciplined portfolio system. This article explores Scimitar’s “AI Value Operating Flywheel,” outlining the structural decisions, governance archetypes, and strategic allocation variables required to ensure AI investments deliver measurable, long-term impact.
| Intended Reader For biopharma CEOs, CFOs, Chief Digital Officers, and Chief Operating Officers evaluating why their AI investments are not yet generating enterprise-scale returns and what it will take to change that. | Key Takeaways The AI value gap in biopharma is not a technology problem: it is a leadership and operating one. More […]
| Intended Reader For biopharma leaders looking to transform their organizations at scale by adopting digital and GenAI solutions. | Key Takeaways Don’t know when to use AI vs automation, here are five categories to help you decide: Accuracy: 100% precision required? Automate. Batch release and dose calculations can’t absorb a 5% error rate. Use […]
Modality Diversity, Target Selection, and Portfolio Strategy Creating a Perfect Storm of Complexity
| Intended Reader Biopharma leaders | Key Takeaways AI-driven Virtual Labs are set to revolutionize biopharma R&D. AI agents successfully designed and validated a groundbreaking therapeutic solution. Accelerated drug discovery can reshape medical progress and patient treatment timelines. 3 minute read In Dario Amodei’s Machines of Loving Grace, he cut through the AI hype and yet […]
| Intended Reader Biopharma leaders | Key Takeaways Harmonization’s impact on RWE and RWD integration Leveraging AI to drive Data Standardization The potential of Harmonization, RWE, and AI to improve patient outcomes The third post in our in a series on the Evolving World of Global Regulatory Affairs 5 minute read For this post in […]
| Intended Reader Biopharma leaders | Key Takeaways Transforming Regulatory Processes with AI AI in Drug Discovery and Development Regulatory Challenges and Ethical Considerations The second post in our in a series on the Evolving World of Global Regulatory Affairs 5 minute read As we continue our series diving into the evolving trends in the […]